z-logo
open-access-imgOpen Access
Immuno-transcriptomic profiling of extracranial pediatric solid malignancies
Author(s) -
Andrew S. Brohl,
Sivasish Sindiri,
Jun S. Wei,
David Milewski,
Hsien-Chao Chou,
Young Song,
Xinyu Wen,
Jeetendra Kumar,
Hue V. Reardon,
Uma Mudunuri,
Jack Collins,
Sushma Nagaraj,
Vineela Gangalapudi,
Manoj Tyagi,
Yuelin J. Zhu,
Katherine E. Masih,
Marielle E. Yohe,
Jack F. Shern,
Yue Qi,
Udayan Guha,
Daniel Catchpoole,
Rimas J. Orentas,
Igor B. Kuznetsov,
Nicolás J. Llosa,
John A. Ligon,
Brian Turpin,
Daniel Leino,
Shintaro Iwata,
Irene L. Andrulis,
Jay S. Wunder,
Sílvia Regina Caminada de Toledo,
Paul S. Meltzer,
Ching C. Lau,
Beverly A. Teicher,
Heather Magnan,
Marc Ladanyi,
Javed Khan
Publication year - 2021
Publication title -
cell reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.264
H-Index - 154
eISSN - 2639-1856
pISSN - 2211-1247
DOI - 10.1016/j.celrep.2021.110047
Subject(s) - transcriptome , biology , immune system , cancer research , t cell receptor , germline , sarcoma , computational biology , immune checkpoint , pediatric cancer , osteosarcoma , antigen , cancer , t cell , immunotherapy , gene , immunology , medicine , genetics , pathology , gene expression
SUMMARY We perform an immunogenomics analysis utilizing whole-transcriptome sequencing of 657 pediatric extra-cranial solid cancer samples representing 14 diagnoses, and additionally utilize transcriptomes of 131 pediatric cancer cell lines and 147 normal tissue samples for comparison. We describe patterns of infiltrating immune cells, T cell receptor (TCR) clonal expansion, and translationally relevant immune checkpoints. We find that tumor-infiltrating lymphocytes and TCR counts vary widely across cancer types and within each diagnosis, and notably are significantly predictive of survival in osteosarcoma patients. We identify potential cancer-specific immunotherapeutic targets for adoptive cell therapies including cell-surface proteins, tumor germline antigens, and lineage-specific transcription factors. Using an orthogonal immunopeptidomics approach, we find several potential immunotherapeutic targets in osteosarcoma and Ewing sarcoma and validated PRAME as a bona fide multi-pediatric cancer target. Importantly, this work provides a critical framework for immune targeting of extracranial solid tumors using parallel immuno-transcriptomic and -peptidomic approaches.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom